Virax Biolabs Group Limited (VRAX) has filed a resale prospectus covering up to 1,682,360 ordinary shares, all to be sold from time to time by existing security holders. These shares consist of 1,644,000 ordinary shares issuable upon exercise of new Series A and Series B preferred investment options and 38,360 shares issuable upon exercise of placement agent warrants. The new warrants have an exercise price of $6.00 per share and the placement agent warrants an exercise price of $7.50 per share, and become exercisable following shareholder approval of an authorized share increase on August 21, 2026, with expirations five years or eighteen months after September 3, 2026, as applicable.
The company will not receive proceeds from any resale of shares by the selling shareholders but may receive cash if the warrants are exercised, which it intends to use as working capital for general corporate purposes. Ordinary shares outstanding were 1,344,988 as of September 2, 2026; this is a baseline figure, not the amount being offered. Virax is a Cayman Islands holding company focused on T cell–based immune profiling and in vitro diagnostic technologies, qualifies as an emerging growth company and a foreign private issuer, and its ordinary shares trade on the Nasdaq Capital Market under the symbol VRAX.
Virax Biolabs Group Ltd (VRAX) has amended its existing at-the-market equity program with H.C. Wainwright & Co., LLC by filing a new sticker prospectus supplement. The amendment increases the maximum aggregate offering amount of Ordinary Shares that may be sold through the Sales Agent under the program to $2,070,060.20. This amount is in addition to $3,658,152 of Ordinary Shares previously sold under the same Sales Agreement. The updated prospectus supplements and Base Prospectus form part of Virax’s effective Registration Statement on Form F-3, and a legal opinion from Ogier regarding the validity of the Ordinary Shares is included as an exhibit.
Virax Biolabs Group Limited (VRAX) updated its at-the-market equity program under its Form F-3 shelf registration, allowing the company to offer and sell up to $2,070,060.20 of ordinary shares from time to time through H.C. Wainwright & Co. under an existing At The Market Offering Agreement. This new capacity is based on General Instruction I.B.5 of Form F-3 and the company’s current public float. The update excludes approximately $3,658,152 of ordinary shares already sold under prior related prospectus supplements. Virax’s ordinary shares trade on the Nasdaq Capital Market under the symbol VRAX, and the company is relying on emerging growth company and foreign private issuer reporting accommodations.
Virax Biolabs Group Limited (VRAX) has filed an amended Form F-3 to register for resale up to 1,682,360 ordinary shares, all to be sold from time to time by existing security holders. These shares consist of 1,644,000 New Warrant Shares and 38,360 Placement Agent Warrant Shares.
Virax will not receive proceeds from any resale of these shares, but may receive cash if investors exercise the underlying warrants, which carry exercise prices of $6.00 and $7.50 per share. Ordinary shares outstanding were 1,344,988 as of September 2, 2026, after a 1-for-25 share consolidation effective June 26, 2026.
Virax Biolabs Group Ltd (VRAX) held an Extraordinary General Meeting process in August 2026 to consider changes to its capital structure and governing documents. An initial meeting on August 14, 2026 lacked a quorum and was adjourned to August 21, 2026, where, under the Articles of Association, the shareholders present after 15 minutes (representing 8.94% of voting shares) constituted a quorum.
Shareholders approved an ordinary resolution to increase authorized share capital from US$50,000 (2,000,000 ordinary shares of US$0.025 par value) to US$12,500,000 (500,000,000 ordinary shares), by creating 498,000,000 additional authorized shares. The vote on this Share Capital Increase was 61,471 for, 54,414 against, and 4,342 abstain. A separate special resolution to adopt a fifth amended and restated memorandum and articles of association to reflect the revised authorized share capital and the effective date of a Share Consolidation did not receive the required two-thirds majority and was not approved, despite votes of 66,754 for, 53,203 against, and 270 abstain.
Virax Biolabs Group Limited reported that on August 18, 2026 it published an updated Q3 2026 investor presentation on its investor relations website. The company is a foreign private issuer that files its annual reports under cover of Form 20-F.
Virax Biolabs Group Limited has called an Extraordinary General Meeting for August 14, 2026 at 2:00 p.m. local time in Glasgow, with a July 27, 2026 record date, for holders of ordinary shares of US$0.025 par value each.
Proposal 1 seeks approval to increase authorized share capital from US$50,000 divided into 2,000,000 ordinary shares to US$12,500,000 divided into 500,000,000 ordinary shares by creating 498,000,000 additional shares. The board states this Share Capital Increase is intended to support basic financing needs, potential business development transactions and the clinical and regulatory development of ViraxImmune™, providing funding and transactional flexibility. Proposal 2 would adopt a fifth amended and restated memorandum and articles of association, replacing the current charter to reflect the new capital structure. Proposal 3 would allow the chair to adjourn the meeting to solicit additional proxies if support is initially insufficient. The board unanimously recommends voting FOR all three proposals, and shareholders may vote in person or by proxy online, by phone or by mail.
Virax Biolabs Group Limited has filed a Form F-3 to register for resale up to 1,682,360 ordinary shares issuable upon exercise of outstanding warrants. These include 1,644,000 New Warrant Shares with a $6.00 exercise price and 38,360 Placement Agent Warrant Shares with a $7.50 exercise price. The company will not receive proceeds from share resales but may receive cash proceeds if the warrants are exercised, which it intends to use for working capital and general corporate purposes.
The warrants only become exercisable after shareholders approve an Authorized Share Increase to expand capital from 2,000,000 to 500,000,000 ordinary shares; approval is uncertain and, without it, the warrants remain unexercisable. Ordinary shares outstanding were 796,988 as of July 24, 2026. Virax recently completed a warrant inducement transaction that generated approximately $3.3 million in gross proceeds and issued new Series A and B preferred investment options. The company remains an emerging growth company and a foreign private issuer, using reduced U.S. reporting requirements.
Virax Biolabs Group Limited published a shareholder update summarizing audited fiscal 2026 results and recent developments. As of March 31, 2026, it reported $6.4 million in cash, $8.3 million in total assets, $1.0 million in total liabilities and $7.3 million in shareholders’ equity attributable to ordinary shareholders. Research and development expenses were $3.7 million versus $2.0 million in fiscal 2025, general and administrative expenses fell to $2.7 million from $4.0 million, and net loss narrowed to $5.0 million from $6.1 million. Subsequent to year-end, Virax raised approximately $3.3 million in gross proceeds from the exercise of preferred investment options.
The company highlighted a multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect research-use-only products across six Southeast Asian markets. Following a 1-for-25 share consolidation, Nasdaq confirmed Virax regained compliance with the minimum bid price requirement. Management also noted that, at a closing price of $3.74 on July 14, 2026, public market valuation was below audited cash and shareholders’ equity despite the recent financing and commercial progress.